Q2 2026 saw 32% year-over-year growth in exome and genome test volumes and 17% revenue growth, with adjusted gross margin steady at 70%. Expansion into new markets and payer coverage, plus a strengthened cash position from a Blackstone transaction, support a positive outlook.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.